Phenotypic Drug Resistance Patterns among Mycobacterium tuberculosis Isolates at the National Tuberculosis Reference Laboratory, Zambia, 2021–2025

Abstract Background Drug-resistant tuberculosis (DR-TB) remains an important challenge to TB control, and characterization of phenotypic resistance patterns is essential for surveillance and appropriate treatment. However, routine laboratory data on resistance to individual first-line anti-TB drugs and specific resistance patterns among isolates referred to the National Tuberculosis Reference Laboratory (NTRL), Zambia, have not been recently described. This study characterized phenotypic resistance patterns and factors associated with multidrug-resistant tuberculosis (MDR-TB) among Mycobacterium tuberculosis isolates processed at the NTRL. Methods A retrospective laboratory-based observational study was conducted using routinely collected NTRL laboratory data between 1 January 2021 and 31 December 2025. Culture-confirmed M. tuberculosis isolates from patients with phenotypic drug susceptibility testing (DST) results for isoniazid, rifampicin, streptomycin and ethambutol were included. Resistance patterns were classified as fully susceptible, monoresistant, polyresistant non-MDR, or MDR-TB. Logistic regression was used to assess factors associated with MDR-TB. Crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. The adjusted model included age, sex, HIV status and previous treatment. Results A total of 172 M. tuberculosis isolates from 172 patients were included. Overall, 76 (44.19%) isolates were resistant to at least one drug. Resistance was highest for isoniazid (64/172, 37.21%; 95% CI: 30.25–44.75), followed by rifampicin (40/172, 23.26%; 95% CI: 17.49–30.22), streptomycin (22/172, 12.79%; 95% CI: 8.54–18.73) and ethambutol (18/172, 10.47%; 95% CI: 6.66–16.06). 96 (55.81%) isolates were fully susceptible, 31 (18.02%) showed monoresistance, 13 (7.56%) showed polyresistance without MDR-TB, and 32 (18.60%) were MDR-TB. Previous second-line treatment was independently associated with MDR-TB (aOR 5.29, 95% CI: 1.77–15.87; P = 0.003). HIV status, sex and age were not significantly associated with MDR-TB. Conclusion A substantial proportion of M. tuberculosis isolates referred to the NTRL showed resistance to first-line anti-TB drugs, with isoniazid resistance being the most common and MDR-TB identified in 18.60% of isolates. Previous second-line treatment was independently associated with MDR-TB. Continued phenotypic DST and routine laboratory surveillance are important for characterizing resistance patterns and supporting the management of DR-TB in Zambia.

Authors

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11282726/v1
Primary Topic
Tuberculosis Research and Epidemiology
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Phenotypic Drug Resistance Patterns among Mycobacterium tuberculosis Isolates at the National Tuberculosis Reference Laboratory, Zambia, 2021–2025

David Kajoba Mumena, Jonathan Mwenya, John Muzyamba, Wilson Nyirenda et al.
Research Square
Tuberculosis Research and Epidemiology
preprint

Phenotypic Drug Resistance Patterns among Mycobacterium tuberculosis Isolates at the National Tuberculosis Reference Laboratory, Zambia, 2021–2025

David Kajoba Mumena, Jonathan Mwenya, John Muzyamba, Wilson Nyirenda, Alex Maleti, Phiri Faliton, Jonathan Simpemba, Beene Muleza Manchishi, Esther Kalito Nyendwa, James Mukamwembo, Kasamba Ng’andu, Alan Musunsa, Wenga Namutowe, Phenister Mwale, Mutende Wina
preprint en

Abstract

Abstract Background Drug-resistant tuberculosis (DR-TB) remains an important challenge to TB control, and characterization of phenotypic resistance patterns is essential for surveillance and appropriate treatment. However, routine laboratory data on resistance to individual first-line anti-TB drugs and specific resistance patterns among isolates referred to the National Tuberculosis Reference Laboratory (NTRL), Zambia, have not been recently described. This study characterized phenotypic resistance patterns and factors associated with multidrug-resistant tuberculosis (MDR-TB) among Mycobacterium tuberculosis isolates processed at the NTRL. Methods A retrospective laboratory-based observational study was conducted using routinely collected NTRL laboratory data between 1 January 2021 and 31 December 2025. Culture-confirmed M. tuberculosis isolates from patients with phenotypic drug susceptibility testing (DST) results for isoniazid, rifampicin, streptomycin and ethambutol were included. Resistance patterns were classified as fully susceptible, monoresistant, polyresistant non-MDR, or MDR-TB. Logistic regression was used to assess factors associated with MDR-TB. Crude and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) were estimated. The adjusted model included age, sex, HIV status and previous treatment. Results A total of 172 M. tuberculosis isolates from 172 patients were included. Overall, 76 (44.19%) isolates were resistant to at least one drug. Resistance was highest for isoniazid (64/172, 37.21%; 95% CI: 30.25–44.75), followed by rifampicin (40/172, 23.26%; 95% CI: 17.49–30.22), streptomycin (22/172, 12.79%; 95% CI: 8.54–18.73) and ethambutol (18/172, 10.47%; 95% CI: 6.66–16.06). 96 (55.81%) isolates were fully susceptible, 31 (18.02%) showed monoresistance, 13 (7.56%) showed polyresistance without MDR-TB, and 32 (18.60%) were MDR-TB. Previous second-line treatment was independently associated with MDR-TB (aOR 5.29, 95% CI: 1.77–15.87; P = 0.003). HIV status, sex and age were not significantly associated with MDR-TB. Conclusion A substantial proportion of M. tuberculosis isolates referred to the NTRL showed resistance to first-line anti-TB drugs, with isoniazid resistance being the most common and MDR-TB identified in 18.60% of isolates. Previous second-line treatment was independently associated with MDR-TB. Continued phenotypic DST and routine laboratory surveillance are important for characterizing resistance patterns and supporting the management of DR-TB in Zambia.

Research Square
Good health and well-being
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon